LCB58A / LigaChem Biosci - LARVOL DELTA

Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload (IASLC-WCLC 2025) - "LCB58A, a set of novel antibody-drug conjugate (ADC) targeting CEACAM5, utilizes a novel IgG1 antibody clone conjugated to LCB's proprietary ConjuAll technology...The ADCs' ability to specifically bind and efficiently internalize offers a significant therapeutic advantage, particularly in tumor environments with high levels of soluble CEACAM5. These findings highlight LCB58As' potential as highly effective treatment options for patients with CEACAM5-expressing solid tumors, representing a promising avenue in cancer therapy."

Clinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CEACAM5

LigaChem Biosciences confirms preclinical efficacy of CEACAM5 ADC with no off-pathway leakage [Google translation] (BioNews) - "Anticipated differentiation in solid tumors, including NSCLC and CRC....The data indicated superior tumor cell binding, enhanced tumor growth inhibition, and a favorable safety profile compared with competing drugs....The company plans to initiate Phase 1 clinical trials in the second quarter of 2027."

New P1 trial • Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer